Navigation Links
ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection
Date:4/18/2008

NEW FDA APPROVAL: THE HIGHEST UVA & UVB PROTECTION IN A SUNSCREEN WITH

MEXORYL(TM) SX

NEW YORK, April 18 /PRNewswire/ -- La Roche-Posay, the brand recommended by 25,000 dermatologists worldwide, announces the FDA approval of ANTHELIOS 40 with the highest photostable UVA and UVB protection available in a sunscreen with Mexoryl(TM) SX. ANTHELIOS 40 Sunscreen is a revolutionary outdoor use sunscreen for the face and body, specifically tested for safety on those with the photosensitive skin disorder, Polymorphous Light Eruption (PMLE).

Photosensitivity is a pervasive issue for people suffering from a variety of photosensitive conditions including, but not limited to, PMLE, Photoallergic Eruption (sun allergies), Phototoxicity, Solar Uticaria (sun rashes) and autoimmune disease. In fact, it is estimated that up to 17% of the US population alone experience symptoms related to PMLE as a result of UV (primarily UVA) exposure(1). These figures are likely understated as many potential patients do not seek treatment for proper diagnosis. In approximately 50% of those affected, the action spectrum is actually UVA rays(2).

UVA rays penetrate deeper than UVB rays and can result in significant skin damage ranging from premature skin aging to skin cancer. It is therefore essential to protect oneself against these harmful rays, especially for those that are more susceptible to the risks associated with UV exposure as a result of photosensitive disorders or autoimmune disease. Proper broad spectrum photo-protection that is effective and safe is an indispensable tool to help manage these very real dangers. According to Dr. Vincent Deleo (board certified New York - Los Angeles based dermatologist), "UV exposure and its related risks are a big concern in my own practice where I see many patients who are photosensitive either because of the drugs they take, skin type or even an autoimmune disease. They absolutely need effective
'/>"/>

SOURCE La Roche-Posay
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Proposes New Rules for Sunscreens
2. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
3. FDA Sunscreen Labeling Decision Delayed Another Month, Leading U.S. Physician to Say, Enough Is Enough
4. Gene-Based Sunscreen Might Someday Prevent Skin Cancer
5. Choose Biodegradable Sunscreen to Save Coral Reefs
6. Renowned Doctor Says Best Way to Obtain Crucial Vitamin D Is From Sun; but Still, Dont Forget Sunscreen
7. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
8. Brandeis neuroscientist wins NIH directors Pioneer Award
9. The Branded Pharmaceutical Association Comments on Hydrocodone
10. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
11. Brands Tackle the Childhood Obesity Issue During M2Moms(TM) - The Marketing-To-Moms Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Vivakor Announces New Acquisition Strategy 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 1Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 2SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 1SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 2SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 3